C. Ponticelli and R. J. Glassock, Glomerular diseases: membranous nephropathy-a modern view, Clin J Am Soc Nephrol, vol.9, pp.609-616, 2014.

A. Schieppati, L. Mosconi, and A. Perna, Prognosis of untreated patients with idiopathic membranous nephropathy, N Engl J Med, vol.8, pp.85-89, 1993.

, Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis, Kidney Int, issue.2, pp.186-197, 2012.

L. H. Beck, R. G. Bonegio, and G. Lambeau, M-type phospholipase A2 receptor as target antigen in idiopathic MN, N Engl Med J, vol.361, pp.11-21, 2009.

P. Ruggenenti, H. Debiec, and B. Ruggiero, Antiphospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy, J Am Soc Nephrol, vol.26, pp.2545-2558, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02193793

J. M. Hofstra, L. H. Beck, and D. M. Beck, Anti-phospholipase A2 receptor antibodies correlate with clinical status in primary membranous nephropathy, Clin J Am Soc Nephrol, vol.6, pp.1286-1291, 2011.

E. Hoxha, I. Thiele, and G. Zahner, Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy, J Am Soc Nephrol, vol.25, pp.1357-1366, 2014.

A. P. Bech, J. M. Hofstra, and P. E. Brenchley, Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.7, pp.1386-1392, 2014.

G. Gupta, H. Fattah, and R. Ayalon, Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation, Clin Transplant, vol.30, pp.461-469, 2016.

K. Dahan, H. Debiec, and E. Plaisier, Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up, J Am Soc Nephrol, vol.28, pp.348-358, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01490466

F. C. Fervenza, G. B. Appel, and S. J. Barbour, Rituximab or cyclosporine in the treatment of membranous nephropathy, N Engl J Med, vol.381, pp.36-46, 2019.

A. S. De-vriese, R. J. Glassock, and K. A. Nath, A proposal for a serology-based approach to membranous nephropathy, J Am Soc Nephrol, vol.28, pp.421-430, 2017.

P. Ruggenenti, C. Chiurchiu, and M. Abbate, Rituximab for idiopathic membranous nephropathy: who can benefit?, Clin J Am Soc Nephrol, vol.1, pp.738-748, 2006.

K. Dahan, V. Gillion, and C. Johanet, The role of PLA2R antibody in treatment of membranous nephropathy, Kidney Int Rep, vol.3, pp.498-501, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02380946

X. J. Zhou, F. D. Zhou, and S. X. Wang, A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: a longterm follow-up, Medicine (Baltimore), vol.97, p.11184, 2018.

B. Seitz-polski, K. Dahan, and H. Debiec, High-dose rituximab and early remission in PLA2R1-related membranous nephropathy, Clin J Am Soc Nephrol, vol.14, pp.1173-1182, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02413171

W. G. Couser, Primary membranous nephropathy, Clin J Am Soc Nephrol, vol.12, pp.983-997, 2017.

J. M. Hofstra, F. C. Fervenza, and J. F. Wetzels, Treatment of idiopathic membranous nephropathy, Nat Rev Nephrol, vol.9, pp.443-458, 2013.

G. Remuzzi, C. Chiurchiu, and M. Abbate, Rituximab for idiopathic membranous nephropathy, Lancet, vol.360, pp.923-924, 2002.

P. Cravedi, P. Ruggenenti, and M. C. Sghirlanzoni, Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.2, pp.932-937, 2007.

P. Ruggenenti, P. Cravedi, and A. Chianca, Rituximab in idiopathic membranous nephropathy, J Am Soc Nephrol, vol.23, pp.1416-1425, 2012.

F. C. Fervenza, F. G. Cosio, and S. B. Erickson, Rituximab treatment of idiopathic membranous nephropathy, Kidney Int, vol.73, pp.117-125, 2008.

J. Floege, S. J. Barbour, and D. C. Cattran, Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, Kidney Int, vol.95, pp.268-280, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02380922

P. W. Du-buf-vereijken, A. J. Branten, and J. F. Wetzels, Cytotoxic therapy for membranous nephropathy and renal insufficiency: improved renal survival but high relapse rate, Nephrol Dial Transplant, vol.19, pp.1142-1148, 2004.

D. C. Cattran, C. Greenwood, and S. Ritchie, Canadian Glomerulonephritis Study Group. A controlled trial of cyclosporine in patients with progressive membranous nephropathy, Kidney Int, vol.47, pp.1130-1135, 1995.

N. Pallet, S. Chauvet, and J. F. Chassé, Urinary retinol binding protein is a marker of extent of interstitial kidney fibrosis, PLoS One, vol.9, p.84708, 2014.

J. Van-den-brand, J. M. Hofstra, and J. F. Wetzetls, Low-molecularweight proteins as prognostic markers in idiopathic membranous nephropathy, Clin J Am Soc Nephrol, vol.6, pp.2846-2853, 2011.

A. E. Van-de-logt, K. Dahan, and A. Rousseau, Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab, Kidney Int, vol.93, pp.1016-1017, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02380978

K. Dahan, C. Johannet, and E. Esteve, Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody, Kidney Int, vol.95, pp.233-234, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02380929

J. Van-den-brand, P. Ruggenenti, and A. Chianca, Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy, J Am Soc Nephrol, vol.28, pp.2729-2737, 2017.